ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Willem Flameng
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flameng, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flameng, W.

Ann Thorac Surg 2005;80:1326
© 2005 The Society of Thoracic Surgeons

Original article: Cardiovascular

Invited commentary

Willem Flameng, MD, PhD

Department of Cardiac Surgery, University Clinic Gasthuisberg, Herestraat 49, Leuven, B-3000 Belgium

(Email: willem.flameng{at}uz.kuleuven.ac.be).

The ultimate test of a new heart valve prosthesis remains the implantation of the device in humans. This is not without risk, and unexpected catastrophic results can be obtained in spite of extensive pre-clinical testing. Therefore it is a relief to see the report of a first clinical trial demonstrating uneventful early results.

To justify such clinical implantation of newly developed heart valves, one expects at least significant advantages on the existing and generally accepted prostheses. In case of the newly designed low-profile Medtronic Advantage valve (Medtronic, Inc, Minneapolis, MN), there could be superior hemodynamics and reduced thrombogenicity.

The present study [1] reveals that the Medtronic Advantage valve performs well hemodynamically as demonstrated by low mean pressure gradients, large effective orifice areas, and indices. Furthermore, the authors performed hemodynamic studies during treadmill exercise 1 year after valve replacement, the ultimate test of heart valve performance. They also found a low incidence of patient–prosthesis mismatch and a significant regression of left ventricular (LV) mass 1 year after valve replacement.

The authors are to be congratulated not only for their carefully performed study, but also for their realistic interpretation of the results. Indeed, a mean pressure gradient ranging from 10.8 to 20.0 mm Hg across all valve sizes during treadmill exercise at 100 W workload is excellent but not superior to the results of existent bileaflet valves. The same holds true for effective orifice area index (EOAI) values between 0.93 and 1.37 cm2/m2, the low incidence of patient-prosthesis mismatch, and an 18% reduction of LV mass at 1 year.

It is unquestionably true that "second generation" bileaflet heart valves perform better than their "first generation" counterparts and that actual heart valves designs did "a good job." In a comparable series of patients for example, we observed EOAI values between 0.60 to 0.92 (across all valve sizes, including size 19) for the older St. Jude Standard bileaflet valve versus 0.91 to 1.37 cm2/m2 for the actual St. Jude Regent valve (St. Jude Medical, St. Paul, MN).

We may confirm the conclusion of the present study that this new bileaflet valve has an excellent hemodynamic profile, but we feel that the advantage of the Medtronic Advantage valve on the existing second generation bileaflet heart valves remains to be elucidated.


   References
Top
 References
 

  1. Guenzinger R, Eichinger WB, Botzenhardt F, et al. Rest and exercise performance of the Medtronic advantage bileaflet valve in the aortic position Ann Thorac Surg 2005;80:1319-1326.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Willem Flameng
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flameng, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flameng, W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS